136 related articles for article (PubMed ID: 35678410)
1. The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance.
Rose RV; Kass JS
Continuum (Minneap Minn); 2022 Jun; 28(3):937-941. PubMed ID: 35678410
[TBL] [Abstract][Full Text] [Related]
2. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
3. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
DiStefano MJ; Alexander GC; Polsky D; Anderson GF
J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's and Aducanumab: Unjust Profits and False Hopes.
Fleck LM
Hastings Cent Rep; 2021 Jul; 51(4):9-11. PubMed ID: 34156732
[TBL] [Abstract][Full Text] [Related]
5. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
6. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
7. Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease.
Lin PJ; Levine A; Rucker J; Chambers JD
Alzheimers Dement; 2023 Aug; 19(8):3654-3669. PubMed ID: 36852834
[TBL] [Abstract][Full Text] [Related]
8. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.
Brockmann R; Nixon J; Love BL; Yunusa I
Lancet Reg Health Am; 2023 Apr; 20():100467. PubMed ID: 36908502
[TBL] [Abstract][Full Text] [Related]
9. Can we learn lessons from the FDA's approval of aducanumab?
Liu KY; Howard R
Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
[TBL] [Abstract][Full Text] [Related]
10. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
11. The Search for a Drug to End Alzheimer's.
Campbell S
IEEE Pulse; 2021; 12(2):2-7. PubMed ID: 33861693
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the First Round of Public Comments for the National Coverage Determination for Monoclonal Antibodies in the Treatment of Alzheimer's Disease.
Wahl J; Gadbois EA
J Aging Soc Policy; 2023 Jul; ():1-20. PubMed ID: 37486161
[TBL] [Abstract][Full Text] [Related]
13. Aducanumab for Alzheimer's disease: A regulatory perspective.
Nisticò R; Borg JJ
Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
[TBL] [Abstract][Full Text] [Related]
14. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
[TBL] [Abstract][Full Text] [Related]
15. Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
Crosson FJ; Covinsky K; Redberg RF
JAMA Intern Med; 2021 Oct; 181(10):1278-1280. PubMed ID: 34254992
[No Abstract] [Full Text] [Related]
16. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.
Herder M
J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277
[TBL] [Abstract][Full Text] [Related]
17. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
18. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
19. Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.
Day GS; Scarmeas N; Dubinsky R; Coerver K; Mostacero A; West B; Wessels SR; Armstrong MJ
Neurology; 2022 Apr; 98(15):619-631. PubMed ID: 35197360
[TBL] [Abstract][Full Text] [Related]
20. What Might Aducanumab Teach Us About Clinicians' Judgment About Whether to Recommend Emerging Alzheimer's Interventions?
Burroughs AW; Krain LP
AMA J Ethics; 2023 Oct; 25(10):E777-782. PubMed ID: 37801063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
